Journal of Endocrinological Investigation

, Volume 29, Issue 2, pp 136–140 | Cite as

High prevalence of adrenal suppression during acute illness in hospitalized patients receiving megestrol acetate

  • A. R. Chidakel
  • S. B. Zweig
  • J. R. Schlosser
  • P. Homel
  • J. W. Schappert
  • A. M. FleckmanEmail author
Original Articles


Introduction: Megestrol acetate (MA) is a progestational agent used for palliation of breast and endometrial cancer. The drug promotes weight gain via appetite stimulation. This property has led to widespread use in patients with wasting illnesses. Increasing numbers of reports suggest glucocorticoid activity. Objective: Unrecognized adrenal suppression may result from MA use. This is the first study to examine the prevalence of adrenal suppression in hospitalized patients treated with MA. Subjects and design: This is a cross-sectional study of hospitalized patients receiving MA compared to control subjects. Morning cortisol levels, endocrine signs and symptoms, and duration of MA therapy were evaluated in 28 hospitalized medical patients treated with MA, and 21 control patients admitted to the same hospital service during the study period. Results: Median cortisol levels were significantly lower in patients using MA vs controls (160 vs 386 nmol/l, p=0.003). Forty-three percent of subjects on MA demonstrated morning cortisol levels below the normal range (138-690 nmol/l), compared with 10% of controls (p=0.013). Ninety-three percent of subjects taking MA had morning cortisol levels below the level that excludes adrenal insufficiency in hospitalized patients (497 nmol/l) vs 71% of controls (p=0.06). Conclusions: MA use is associated with significant adrenal suppression in acutely ill individuals. This should alert physicians to the possibility of adrenal insufficiency and the need to assess for signs or symptoms of adrenal insufficiency, and mandates a low threshold for testing adrenal function in hospitalized patients taking MA.


Megestrol acetate adrenal insufficiency HIV cancer glucocorticoids 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Stuart NS, Warwick J, Blackledge GR, et al. A randomized phase III cross-over study of tamoxifen vs. megestrol acetate in advanced and recurrent breast cancer. Eur J Cancer 1996, 32A: 1888–92.PubMedCrossRefGoogle Scholar
  2. 2.
    Dranitsaris G, Leung P, Mather J, Oza A. Cost-utility analysis of second-line hormonal therapy in advanced breast cancer: a comparison of two aromatase inhibitors to megestrol acetate. Anticancer Drugs 2000, 11: 591 -601.PubMedCrossRefGoogle Scholar
  3. 3.
    Loprinzi CL, Ellison NM, Schaid DJ, et al. Controlled trial of megestrol acetate for the treatment of cancer anorexia and cachexia. J Natl Cancer Inst 1990, 82: 1127–32.PubMedCrossRefGoogle Scholar
  4. 4.
    Loprinzi CL, Michalak JC, Schaid DJ, et al. Phase III evaluation of four doses of megestrol acetate as therapy for patients with cancer anorexia and/or cachexia. J Clin Oncol 1993, 11: 762–7.PubMedGoogle Scholar
  5. 5.
    McMillan DC, Wigmore SJ, Fearon KCH, O’Gorman P, Wright CE, McArdle CS. A prospective randomized study of megestrol acetate and ibuprofen in gastrointestinal cancer patients with weight loss. Brit J Cancer 1999, 79: 495–500.PubMedCentralPubMedCrossRefGoogle Scholar
  6. 6.
    Von Roenn JH, Armstrong D, Kotler DP, et al. Megestrol acetate in patients with AIDS-related cachexia. Ann Intern Med 1994, 121: 393–9.CrossRefGoogle Scholar
  7. 7.
    Oster MH, Enders SR, Samuels SJ, et al. Megestrol acetate in patients with AIDS and cachexia. Ann Intern Med 1994, 121: 400–8.PubMedCrossRefGoogle Scholar
  8. 8.
    Nemechek PM, Polsky B, Gottlieb MS. Treatment guidelines for HIV-associated wasting. Mayo Clin Proc 2000, 75: 386–94.PubMedCrossRefGoogle Scholar
  9. 9.
    Mann M, Koller E, Murgo A, Malozowski S, Bacsanyi J, Leinung M. Glucocorticoidlike activity of megestrol: a summary of Food and Drug Administration experience and a review of the literature. Arch Intern Med 1997, 157: 1 651 -6.CrossRefGoogle Scholar
  10. 10.
    Henry JB. Clinical diagnosis and management by laboratory methods. Philadelphia: W.B. Saunders Co. 1996, 353–7.Google Scholar
  11. 11.
    Aron DC. Diagnostic implications of adrenal physiology and clinical epidemiology for evaluation of glucocorticoid excess and deficiency. In: DeGroot LJ, Jameson JL, Burger HG, et al. eds. Endocrinology. 4th ed. Philadelphia: W.B. Saunders Co. 2001, 1655–70.Google Scholar
  12. 12.
    Grinspoon SK, Biller BMK. Laboratory assessment of adrenal insufficiency. J Clin Endocrinol Metab 1994, 79: 923–31.PubMedGoogle Scholar
  13. 13.
    Leinung M, Koller EA, Fossler MJ. Corticosteroid effects of megestrol acetate. The Endocrinologist 1998, 8: 153–9.CrossRefGoogle Scholar
  14. 14.
    Sullivan PS, Dworkin MS, Jones JL, Hooper WC, the Adult/ Adolescent Spectrum of HIV Disease Project. Epidemiology of thrombosis in HIV-infected individuals. AIDS 2000, 14: 321–4.PubMedCrossRefGoogle Scholar
  15. 15.
    Steer KA, Kurtz AB, Honour JW. Megestrol-induced Cushing’s syndrome. Clin Endocrinol (Oxf) 1995, 42: 91–3.CrossRefGoogle Scholar
  16. 16.
    Padmanabhan S, Rosenberg AS. Cushing’s syndrome induced by megestrol acetate in a patient with AIDS. Clin Infect Dis 1998, 27: 217–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Axelrod L. Glucocorticoid therapy. In: DeGroot LJ, Jameson JL, Burger HG, et al. eds. Endocrinology, 4th ed. Philadelphia: W.B. Saunders Co. 2001, 1671–82.Google Scholar
  18. 18.
    Kontula K. Paavonen T. Luukkainen T. Andersson LC. Binding of progestins to the glucocorticoid receptor. Correlation to their glucocorticoid-like effects on in vitro functions of human mononuclear leukocytes. Biochemical Pharmacol 1983, 32: 1511–8.Google Scholar
  19. 19.
    Graham KK, Mikolich DJ, Fisher AE, Posner MR, Dudley MN. Pharmacologic evaluation of megestrol acetate oral suspension in cachectic AIDS patients. J AIDS 1994, 7: 580–6.Google Scholar
  20. 20.
    Timpone JG, Wright DJ, Li N, et al. The safety and pharmacokinetics of single-agent and combination therapy with megestrol acetate and dronabinol for the treatment of HIV wasting syndrome. DATRI 004 Study Group. AIDS Res Hum Retrovir 1997, 13: 305–15.CrossRefGoogle Scholar
  21. 21.
    Briggs MH, Briggs M. Glucocorticoid properties of progestogens. Steroids 1973, 22: 555–9.PubMedCrossRefGoogle Scholar
  22. 22.
    Armstrong L. Drugs and hormones used in endocrinology. In: DeGroot LJ, Jameson JL, Burger HG, et al. eds. Endocrinology, 4th ed. Philadelphia: W.B. Saunders Co. 2001, 2602.Google Scholar
  23. 23.
    Loprinzi CL, Kugler JW, Sloan JA, et al. Randomized comparison of megestrol acetate versus dexamethasone versus fluoxymesterone for the treatment of cancer anorexia/ cachexia. J Clin Oncol 1999, 17: 3299–306.PubMedGoogle Scholar
  24. 24.
    Lamberts SW, Uitterlinden P, Bons EG, Verleun T. Comparison of the actions of RU 38486 and megestrol acetate in the model of a transplantable adrenocorticotropin- and prolactin-secreting rat pituitary tumor. Cancer Res 1985, 45: 1015–9.PubMedGoogle Scholar
  25. 25.
    Lambert A, Frost J, Mitchell R, Wilson AU, Robertson WR. On the site of action of the anti-adrenal steroidogenic effect of etomidate and megestrol acetate. Clin Endocrinol (Oxf) 1984, 21: 721–7.CrossRefGoogle Scholar
  26. 26.
    Lundgren S, Helle SI, Lønning PE. Profound suppression of plasma estrogens by megestrol acetate in postmenopausal breast cancer patients. Clin Cancer Res 1996, 2: 1515–21.PubMedGoogle Scholar
  27. 27.
    Naing KK, Dewar JA, Leese GP. Megestrol acetate therapy and secondary adrenal suppression. Cancer 1999, 86: 1044–9.PubMedCrossRefGoogle Scholar
  28. 28.
    Loprinzi CL, Jensen MD, Jiang NS, Schaid DJ. Effect of megestrol acetate on the human pituitary-adrenal axis. Mayo Clin Proc 1992, 67: 1160–2.PubMedCrossRefGoogle Scholar
  29. 29.
    Leinung MC, Liporace R, Miller CH. Induction of adrenal suppression by megestrol acetate in patients with aids. Ann Intern Med 1995, 122: 843–5.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2006

Authors and Affiliations

  • A. R. Chidakel
    • 1
  • S. B. Zweig
    • 1
  • J. R. Schlosser
    • 1
  • P. Homel
    • 2
  • J. W. Schappert
    • 3
  • A. M. Fleckman
    • 1
    Email author
  1. 1.Division of Endocrinology and Metabolism, Department of MedicineBeth Israel Medical CenterNew YorkUSA
  2. 2.Department of BiostatisticsNew YorkUSA
  3. 3.Department of Diagnostic Pathology and Laboratory MedicineBeth Israel Medical Center, Albert Einstein College of MedicineNew YorkUSA

Personalised recommendations